JT Stratford LLC Decreases Stock Holdings in Pfizer Inc. $PFE

Key Points

• JT Stratford LLC decreased its position in Pfizer Inc. by 58.3% during the first quarter, owning 10,162 shares worth $258,000 after selling 14,191 shares.
• Analysts have recently adjusted price targets for Pfizer, with Morgan Stanley raising it from $32.00 to $33.00 while the average target price is set at $28.12.
• Pfizer announced a quarterly dividend of $0.43 per share, with a yield of 6.8%, to be paid on September 2nd.

JT Stratford LLC reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 58.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,162 shares of the biopharmaceutical company's stock after selling 14,191 shares during the period. JT Stratford LLC's holdings in Pfizer were worth $258,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. William B. Walkup & Associates Inc. boosted its position in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co raised its stake in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its stake in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG boosted its holdings in Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after acquiring an additional 485 shares in the last quarter. Finally, MSH Capital Advisors LLC grew its stake in shares of Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after acquiring an additional 485 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Wolfe Research lifted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Finally, Redburn Atlantic dropped their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

PFE opened at $25.2950 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a 50 day moving average of $24.64 and a two-hundred day moving average of $24.41. The firm has a market capitalization of $143.82 billion, a PE ratio of 13.45, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the firm earned $0.60 EPS. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.